Effects of Aquamin F on NSAID Dose Reduction in Osteoarthritis of the Knee

Inclusion Criteria: * Subjects aged 35 to 75, male or female * Subjects diagnosed with symptomatic moderate to severe osteoarthritis of the knee according to the modified criteria of the American College of Rheumatology 17,18 * Subjects who present with osteoarthritis of the knee as judged by symptoms and disabilities detectable through published, validated questionnaires or previous diagnosis by a physician * subjects who are symptomatic with daily or near daily pain and stiffness from osteoarthritis * subjects who are taking non-steroidal anti-inflammatory drugs (NSAIDs) prior to study enrollment * subjects who are willing to stop NSAIDS and use acetaminophen for pain management during the trial * subjects with screening WOMAC osteoarthritis index total score (transformed score) of not more than 75 * subjects with ability to comprehend and complete the questionnaires and forms * subjects whose schedules permit clinical evaluations every four weeks * subjects who are willing to stop taking calcium supplements, if any and to restrict consumption of high calcium food to 600mg (two dairy servings) per day * subjects with a high probability of compliance with study procedures and test article consumption * subjects willing and able to follow protocol guidelines and schedules and complete diaries * subjects who are likely to abstain from taking unathorized supplements or participating in any other clinical trial or experimental treatment during this trial * subjects with normal gastrointestinal digestion and absorption Exclusion Criteria: * subjects who have a history of inflammatory arthritis, gout, pseudogout, Paget's disease, seizure disorder, insulin dependent diabetes mellitus, uncontrolled hypertension, unstable cardiovascular disease, active hepatic or renal disease, active cancer and/or HIV infection * subjects who are non-ambulatory or bedridden due to osteoarthritis * subjects who are dependent on prescription drugs to control pain * subjects on any other clinical trial or experimental treatment in the past 3 months * subjects who are pregnant, lactating or at risk of becoming pregnant * subjects who have received : intramuscular corticosteroid injection or systemic corticosteroid administration within 4 weeks prior to study enrollment, intra-articular corticosteroid injection within 2 months prior to study enrollment or intra-articular hyaluronic acid injection within 4 months prior to study enrollment.